Boston Scientific's stent, already available in Europe, is expected to provide intense competition for Johnson & Johnson's device. Analysts predict the market for drug-eluting stents will hit $5 billion by 2005.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||